Capricor Therapeutics Inc (OTCMKTS:CAPR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday. The brokerage currently has a $1.25 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 14.68% from the stock’s previous close.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

Several other research firms also recently weighed in on CAPR. HC Wainwright set a $2.00 price target on shares of Capricor Therapeutics and gave the company a “buy” rating in a research note on Monday. Rodman & Renshaw reaffirmed a “buy” rating and issued a $2.15 price objective on shares of Capricor Therapeutics in a research report on Saturday, July 22nd. Finally, ValuEngine cut shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $4.35.

Shares of Capricor Therapeutics (OTCMKTS CAPR) traded up 2.83% during trading on Wednesday, reaching $1.09. The company had a trading volume of 457,204 shares. The company’s market cap is $24.63 million. Capricor Therapeutics has a 12 month low of $0.63 and a 12 month high of $4.09. The firm has a 50 day moving average price of $0.98 and a 200 day moving average price of $1.99.

Capricor Therapeutics (OTCMKTS:CAPR) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The business had revenue of $1 million for the quarter, compared to the consensus estimate of $1.10 million. Analysts predict that Capricor Therapeutics will post ($0.74) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Upgrades Capricor Therapeutics Inc (CAPR) to “Buy”” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at

A hedge fund recently raised its stake in Capricor Therapeutics stock. LLBH Private Wealth Management LLC raised its position in shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) by 27.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 184,591 shares of the biotechnology company’s stock after buying an additional 40,000 shares during the period. LLBH Private Wealth Management LLC owned 0.82% of Capricor Therapeutics worth $153,000 as of its most recent filing with the SEC.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Get a free copy of the Zacks research report on Capricor Therapeutics (CAPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with's FREE daily email newsletter.